Matthias Ilmer et al.
Molecular cancer therapeutics, 14(12), 2712-2721 (2015-10-31)
The substance P (SP)/NK-1 receptor (NK1R) complex represents an intriguing anticancer target for a variety of tumors, including hepatoblastoma (HB). Therefore, NK1R antagonists, such as the clinical drug aprepitant, recently have been proposed as potent anticancer agents. However, very little